ARVINAS, INC.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: Arvinas’ to drive innovation across its PROTAC degrader portfolio and deliver transformative therapies to patients; Arvinas’ plans to initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy and the timing thereof; Arvinas’ plans to present initial data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson’s disease and the timing thereof; Arvinas’ plans to share preclinical data of ARV-393 in combination with glofitamab in models of aggressive high grade DLBCL at the American Society of Hematology Annual Meeting; Arvinas’ plans to share updated clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with NHL at a medical congress, and the timing thereof; Arvinas’ plans to initiate enrollment in a Phase 1 clinical trial of ARV-393 in combination with glofitamab in patients with DLBCL and the timing thereof; Arvinas’ plans to continue enrollment in the Phase 1 trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutation; Arvinas’ plans to share initial clinical data of ARV-806 in patients with solid tumors harboring KRAS G12D mutations and the timing thereof; Arvinas plans to initiate a first-in-human Phase 1 clinical trial of ARV-027 in healthy volunteers, pending regulatory feedback, and the timing thereof; Arvinas’ plans to present preclinical data for ARV-6723 at the Society for Immunotherapy of Cancer Annual Meeting in 2025; Arvinas’ plans to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors, pending regulatory feedback, and the timing thereof; Arvinas’ and Pfizer’s plans to identify and select a partner with the capabilities and expertise to maximize the commercial potential of vepdegestrant; and statements regarding Arvinas’ cash, cash equivalents and marketable securities, including their sufficiency to fund planned operating expenses and capital expenditure requirements into the second half of 2028. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-393, ARV-102 and ARV-806, and including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials and preclinical studies on its expected timelines or at all; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; risks related to Arvinas’ expectations regarding the potential clinical benefit of its product candidates; risks and uncertainties related to the identification of a third party for the commercialization of vepdegestrant; uncertainties relating to regulatory applications and related approval timelines, including with respect to the New Drug Application for vepdegestrant; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority or whether regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of product candidates, including vepdegestrant; risks related to the ability to identify and attract a qualified candidate to serve as Arvinas’ next chief executive officer; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; the impact of the previously announced workforce reductions on Arvinas’ business and reputation; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.